MOG and myeloid sarcoma: The necessity of PVMs in MS was assessed in a most recent study with MHC‐II depletion (Iablox/lox) in selected CNS APCs.85 CD4+ T cells from 2D2 TCR (or MOG 35‐55 specific TCR) transgenic mice were primed by MOG 35‐55, followed by transferring to recipient mice with selective MHC‐II deletion in different APC populations.